Rocket Lab said it is delaying the launch of its Neutron rocket until next year. Shares slid 8% to $54.64 in after-hours trading Wednesday.
Vanda Pharmaceuticals said its Phase 3 trial of a social-anxiety treatment failed to meet its endpoint. The stock declined 6% to $3.95 after the bell.
Netcapital said it had regained compliance with Nasdaq's minimum bid rule. Shares gained 36% to $2.16.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.